New York (January 8th, 2013) - Advanced Cell Technology, Inc. (OTCQB:ACTC) Robert Lanza, M.D., chief scientific officer of ACTC recently stated “They offer the possibility to generate a non-controversial, unlimited source of patient-specific stem cells without embryo destruction. Owing to their short storage time, there is a constant demand for this life-saving blood component. Since platelets don’t contain any genetic material, they cannot form tumors, which makes them ideal for the first clinical trial involving the iPS cell technology. We hope to initiate the first clinical trial using these promising cells in 2013.” Advanced Cell Technology, Inc. (“ACT”; OTCBB: ACTC or the “Company”), a leader in the field of regenerative medicine, announced that chairman and CEO Gary Rabin will present at Biotech Showcase 2013 on Tuesday, Jan. 8, in San Francisco.
Get the latest news on ACTC by getting the free full report here:
Federal National Mortgage Association (OTCQB:FNMA). Fannie Mae (FNMA/OTC) announced that it will not utilize its first (December 12th) Benchmark Notes announcement date this month. As announced in our 2012 Benchmark Securities Issuance Calendar, the company may forego any scheduled Benchmark Notes issuance. Fannie Mae is a leading provider of mortgage credit in the United States. FNMA states – We guarantee and purchase loans so that families can buy homes, refinance their existing mortgages, or access affordable rental housing. Fannie Mae is focused on assisting homeowners in distress, stabilizing neighborhoods, and encouraging sustainable lending. We are committed to improving our financial condition and our priorities are aligned with the public interest. Our work supports the housing recovery today and is helping to build a better housing finance system for the future.